Innovative formulation of microencapsulated "spirubiotic sachets" as a synbiotic treatment for metabolic syndrome patients.

Spirulina platensis (Sp) and probiotic bacteria (Pb) have been shown to have beneficial effects in controlling metabolic syndrome (MeS), characterized by the co-occurrence of obesity, dyslipidemia, hypertension, and type 2 diabetes. The objective of this research was to formulate an innovative microencapsulated powder consisting of a mixture of Sp and Pb, referred to as a "spirubiotic sachet," and investigate its potential positive impact in managing hyperlipidemia, weight gain, hyperglycemia, and related problems in individuals with metabolic syndrome. Microencapsulated Sp with whey protein, flavored with a coconut taste, was obtained by spray drying, and HPLC analysis was performed. Probiotic bacteria were microencapsulated by freeze-drying, and the characterization of both microcapsules was done. The spirubiotic sachets contained both Sp and Pb. Physico-sensory tests were reported. Fifty diagnosed MeS cases were enrolled in this study. Pre- and post-treatment assessments of clinical, dietary, anthropometric data, and body composition measurements were conducted. Enzymatic colorimetric methods and ELISA kits were used to assess biochemical parameters. Patients received one spirubiotic sachet/day and a tailored diet regimen for 3 months. Administering a spirubiotic sachet to MeS patients effectively reversed the majority of metabolic abnormalities, bringing them closer to normal levels with decreased dietary calories, improved anthropometric measures, altered body composition, and normalized biochemical parameters. In conclusion, Sp and Pb work together synergistically to help manage people with MeS and related diseases. Spirubiotic sachets can be innovative with beneficial health effects.